

### **QUERY 1**

Please submit an updated manufacturing schedule for June 1 through October 31, 2021, that details upstream and downstream operations for BNT162b2 drug substance manufacturing in both (b) (4) and (b) (4) at Wyeth BioPharma Division of Wyeth Pharmaceuticals LLC facility (FEI: 1222181) in Andover, MA in support of BLA 125742/0.

### **RESPONSE 1**

#### **Andover:**

The production of the BNT162b2 drug substance includes (b) (4) through final dispense of the drug substance.

(b) (4) will be in active production from 01 June 2021 through 31 October 2021, except for 04 July 2021 through 10 July 2021 due to summer holiday for the associated personnel.

(b) (4) will be in active production from 01 June 2021 through 31 October 2021, except for 04 July 2021 through 10 July 2021 due to summer holiday for the associated personnel.

(b) (4) to support future BNT162b2 drug substance production demands, in (b) (4) are currently anticipated to occur between 01 June 2021 and 04 June 2021 and then from 19 July 2021 through 07 August 2021. The production schedule is dynamic and subject to change.

#### **Literature References**

None

#### **SUPPORTING DOCUMENTATION**

##### **New or Replaced Supporting Documentation**

None

##### **Previously submitted supporting documentation**

None

090177e1971b72c4\Approved\Approved On: 24-May-2021 13:15 (GMT)

## **QUERY 2**

Please submit an updated manufacturing schedule for June 1 through October 31, 2021, that details lipid nanoparticle formulation and fill/finish operations for BNT162b2 drug product manufacturing at both Pfizer Manufacturing Belgium NV facility (FEI: 1000654629) in Puurs, Belgium and Pharmacia & Upjohn Company LLC. facility (FEI: 1810189) in Kalamazoo, MI in support of BLA 125742/0. Please include production schedules for each filling line.

## **RESPONSE 2**

### **Kalamazoo:**

Kalamazoo will be in active production of BNT162b2 in all LNP formulation areas, filling lines (Line (b) (4) ), and packaging lines from 01 June 2021 to 31 October 2021 with no planned facility or production shutdowns. An additional area supporting LNP formulation for emergency use and eventual licensure will be available from 26 July 2021 to 31 October 2021.

### **Puurs:**

Puurs will be in active production of BNT162b2 in various LNP formulation areas, filling lines (b) (4) ), and packaging lines from 01 June 2021 to 31 October 2021. However, production activities are reduced starting from 05 July 2021 until 05 September 2021, due to (b) (4) scheduled in the formulation booths and filling lines. Additional details are provided in the response to Query 3.

### **Literature References**

None

### **SUPPORTING DOCUMENTATION**

#### **New or Replaced Supporting Documentation**

None

#### **Previously submitted supporting documentation**

None

090177e1971b72c4\Approved\Approved On: 24-May-2021 13:15 (GMT)

### **QUERY 3**

Please provide clarification regarding (b) (4) of the Puurs, Belgium facility. As noted in the BLA Section 3.2.R Manufacturing Schedules, production of the COVID-19 vaccine may not be occurring during these timeframes: May 31, 2021, – June 06, 2021, and July 10, 2021, – Sept 06, 2021. Please provide clarification if this applies to all COVID-19 vaccine manufacturing (formulation and/or fill/finish) or select operations.

### **RESPONSE 3**

An audit by the Belgian health authority (FAGG) has been scheduled from 31 May 2021 to 06 June 2021. Therefore, while BNT162b2 production will occur during this time period, it was indicated as not preferable.

In addition, due to (b) (4) during July and August, BNT162b2 production (b) (4) including production in some manufacturing areas producing BNT162b2 COVID-19 Vaccine, but not included in the BLA (see Table 1 and Figure 1 below). Finally, the period prior to, during, and immediately following (b) (4) are scheduled as summer holidays for associated personnel (including many BNT162b2 subject matter experts (SMEs)).

A detailed shutdown schedule is provided in Table 1 and Figure 1 below.

**Table 1. Shutdown Versus Active Manufacturing at Pfizer Puurs**

Manufacturing Activity	Manufacturing Area	Shutdown*	Active Manufacturing
(b) (4)			

090177e1971b72c4\Approved\Approved On: 24-May-2021 13:15 (GMT)

**Figure 1: Shutdown Versus Active Manufacturing at Pfizer Puurs**

(b) (4)



As indicated above, the availability of BNT162b2 SMEs on site during this period is strongly aligned with the production scheme. Therefore, the Puurs site will be manufacturing BNT162b2 at full capacity from 01 Jun 2021 until 05 July 2021, and again starting from 06 September 2021 through 31 October 2021.

**Literature References**

None

**SUPPORTING DOCUMENTATION**

None

090177e1971b72c4\Approved\Approved On: 24-May-2021 13:15 (GMT)

#### **QUERY 4**

Please provide the COVID-19 precautions taken at each manufacturing facility related to visitor entry requirements. At a minimum, please include the maximum number of visitors/inspectors and the necessity of vaccine status/negative COVID-19 test result for entry into your facility.

#### **RESPONSE 4**

##### **Andover and Kalamazoo:**

All visitors to the U.S. Pfizer sites must adhere to the state restrictions and guidelines. The current COVID-19 information for each state can be found by accessing the following links:

- Massachusetts: <https://www.mass.gov/info-details/covid-19-updates-and-information>
- Michigan: <https://www.michigan.gov/coronavirus/>

In addition, all visitors to the Pfizer Andover and Pfizer Kalamazoo sites must follow Pfizer restrictions and guidelines to ensure the safety of those on site. There is no requirement regarding COVID-19 vaccination or to produce a negative COVID-19 test result. However, Pfizer site requirements are more restrictive than the state orders regarding screening questions, social distancing, and hygiene practices, as well as contact tracing as noted below.

There are no maximum number of visitors to the site, however, due to reduced room capacities due to COVID-19 restrictions, which are strictly enforced, sites limit the number of visitors to ensure social distancing. Conference rooms are at a reduced capacity with table decals denoting 6' social distancing space. Pfizer would also like to ensure an inspection can be supported effectively given the pandemic requirements and therefore would like this to be considered.

Screening questions will be required to be addressed by all visitors upon arrival at the site. If the answer to any of the questions is “yes,” you will be asked to contact your host and talk with the Pfizer nurse practitioner. Precautions and protocols to be followed while on site are also included below.

1. Screening questions (Please answer Yes or No)
  - Have you travelled internationally in the past 14 days?
  - Are you feeling unwell currently?
  - Have you had any symptoms of influenza like illness (ILI) in the past 14 days?
  - Have you been in contact with anyone confirmed/presumed to have COVID-19 or ILI in the past 14 days?
2. While on site, Pfizer has implemented the following precautions and protocols:
  - The following must be followed:
    - Social distancing and hygiene practices
      - Plan on maintaining social distance at all times on site (6ft from others)

090177e1971b72c4\Approved\Approved On: 24-May-2021 13:15 (GMT)

- If close work is required (<6ft), the host must perform social distance risk assessment to determine appropriate control (e.g., barriers) or added PPE (Personal Protection Equipment) (e.g., face shield in addition to mask).
- Mask wearing is required unless eating or drinking.
- Mask wearing outside is waived as long as social distancing can be maintained (>6ft).
- Mask to be worn upon exiting vehicle once arriving on site unless social distancing can be maintained from others (>6ft).
- Avoid touching face or exterior of mask.
- Hand washing/sanitizing must occur frequently.
- Please note that contact tracing must be recorded daily while on site, even if no contacts are identified. Your host will be responsible for confirming completion and assure the location where the majority of time spent (e.g. room number) is documented.

The Pfizer sites are continually monitoring data from the surrounding areas and assessing the situation. Any changes to the above restrictions and policies will be communicated.

**Puurs:**

The COVID-19 precautions to be taken are dependent on the guidelines from the Belgian Authorities at the time of visit and are updated daily. Every visitor coming by plane should fill in a Passenger Locator Form (PLF), specific requirements depend on the color code of your country. At the moment, the United States is indicated as a ‘red zone’, therefore, a negative PCR-test is required for any stay longer than 48 hours (test result not older than 72 hours before departure). A quarantine of 7 days is required with the exception of the visit on site. More information can be found at the official Belgian website ‘<https://www.info-coronavirus.be/en/colour-codes-by-country/>’ and in the documents provided ([Guidelines for Business Travel from a Red Zone to Belgium](#) and [Requirements for Travel to Belgium](#)).

In addition, visitor access at Pfizer, Puurs is only possible if the following questions can be answered as ‘No’. In case the answer to any of these questions is ‘yes’, the visit will be rescheduled.

Question	Response
Have you been on holiday for more than 48 hours in a country which, according to the website <sup>a</sup> of the Belgian government, is a dark orange or red zone?	Yes or No
Have you or a member of your household been in contact over the last 14 days with anyone who has been diagnosed with COVID-19?	Yes or No
Are you or a member of your household currently waiting for the result of a COVID-19 test?	Yes or No
Are you currently unwell, with symptoms including fever, high temperature, cough, or sore throat?	Yes or No

a. <https://www.info-coronavirus.be/en/colour-codes-by-country/>

090177e1971b72c4Approved\Approved On: 24-May-2021 13:15 (GMT)

For non-residents travelling to Belgium from a red zone, the questions below in the declaration should be answered as ‘OK’ and signed for agreement upon arrival on site.

Declaration				Signed in agreement:
	<b>OK</b>	<b>NOK</b>		Name of company:
I have the certificate for the exception to quarantine for critical functions and have evidence of this	<input type="checkbox"/>	<input type="checkbox"/>		Surname and first name:
	<b>OK</b>	<b>NOK</b>	<b>NA</b>	Signature:
My stay in Belgium is less than 48 hrs and my transport is not by boat or plane, I do not need a PCR-test and PLF form.	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
My stay in Belgium is less than 48 hrs and my transport is by boat or plane, I’ve completed and submitted a PLF (Passenger Locator Form) and have evidence of this.	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
My stay in Belgium is longer than 48 hrs, I’ve completed and submitted a PLF (Passenger Locator Form) and have evidence of this.	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
I have evidence of a recent negative PCR test result (i.e. less than 72 hours old).	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	

All visitors to the Pfizer Puurs site must follow Pfizer restrictions and guidelines regarding social distancing, hygiene and masks to ensure the safety of those on site. There are no maximum number of visitors to the site, however, due to reduced room capacities due to COVID-19 restrictions, which are strictly enforced, sites limit the number of visitors to ensure social distancing. Conference rooms are at a reduced capacity with table decals denoting 1.5 m social distancing space. Pfizer would also like to ensure an inspection can be supported effectively given the pandemic requirements and therefore would like this to be considered.

**Literature References**

None

**SUPPORTING DOCUMENTATION**

**New or Replaced Supporting Documentation**

[3.2.R Guidelines for Business Travel from a Red Zone to Belgium](#), new

[3.2.R Requirements for Travel to Belgium](#), new

**Previously submitted supporting documentation**

None

090177e1971b72c4\Approved\Approved On: 24-May-2021 13:15 (GMT)